Glioblastoma: Potential Role of Induced Pluripotent Stem Cells in Personalized Medicine
Kush Rao
25/09/2026
In recent years great advances have occurred in the field of oncology. However, one cancer that is yet to be fully understood is glioblastoma, a highly aggressive Grade IV type of glioma. This lack of understanding is largely caused by the heterogeneity of glioblastoma which leads to differences in patient symptoms, difficulty in treatment with common approaches (like chemotherapy), and difficulty in the prognosis of the disease. In order to combat these challenges, scientists are turning to emerging new approaches, one of which is the utilization of induced pluripotent stem cells (iPSCs) to generate cerebral organoids that model aspects of the human brain environment. iPSC-derived cerebral organoids are distinct from patient-derived glioblastoma organoids, which are generated directly from tumor tissue, and from hybrid models that combine patient-derived tumor material with iPSC-derived cerebral organoids. These different experimental platforms may contribute to personalized glioblastoma research by allowing researchers to study tumor behavior, treatment response, and tumor interactions with surrounding brain tissue in different ways. Current studies, however, primarily demonstrate experimental disease modeling and drug-response testing rather than validated clinical decision-making. Further prospective validation, improved reproducibility, practical turnaround times, and stronger correlation between organoid responses and patient outcomes are needed before these approaches can be considered for routine clinical use.